The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos, Ayoma D. Attygalle, Iguaracyra Araújo, Emilio Berti, Govind Bhagat, Anita Borges, Daniel F. Boyer, Maria Calaminici, Amy Chadburn, John K. C. Chan, Wah Cheuk, Wee Joo Chng, John Choi, Shih‐Sung Chuang, Sarah E. Coupland, Magdalena Czader, Sandeep S. Davé, Daphne de Jong, Ming‐Qing Du, Kojo S.J. Elenitoba‐Johnson, Judith A. Ferry, Julia T. Geyer, Dita Gratzinger, Joan Guitart, Sumeet Gujral, Marian H. Harris, Christine J. Harrison, Sylvia Hartmann, Andreas Hochhaus, Patty M. Jansen, Kennosuke Karube, Werner Kempf, Joseph D. Khoury, Hiroshi Kimura, Wolfgang Hiddemann, Alexandra E. Kovach, Shaji Kumar, Alexander J. Lazar, Stefano Lazzi, Lorenzo Leoncini, Nelson Leung, Vasiliki Leventaki, Xiao‐Qiu Li, Megan S. Lim, Weiping Liu, Abner Louissaint, Andrea N. Marcogliese, L. Jeffrey Medeiros, Michael Michal, Roberto N. Miranda, Christina Mitteldorf, Santiago Montes‐Moreno, William G. Morice, Valentina Nardi, Kikkeri N. Naresh, Yasodha Natkunam, Siok‐Bian Ng, Ilske Oschlies, German Ott, Marie Parrens, Melissa Pulitzer, S. Vincent Rajkumar, Andy C. Rawstron, Karen L. Rech, Andreas Rosenwald, Jonathan Said, Clémentine Sarkozy, Shahin Sayed, Caner Saygin, Anna Schuh, William A. Sewell, Reiner Siebert, Aliyah R. Sohani, Reuben Tooze, Alexandra Traverse‐Glehen, Francisco Vega, B. Vergier, Ashutosh Wechalekar, Brent L. Wood, Luc Xerri, Wenbin Xiao
Abstract
Abstract We herein present an overview of the upcoming 5 th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we highlight and explain changes from the revised 4 th edition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5 th edition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms.